1. Home
  2. DLTR vs ALNY Comparison

DLTR vs ALNY Comparison

Compare DLTR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar Tree Inc.

DLTR

Dollar Tree Inc.

N/A

Current Price

$140.24

Market Cap

25.1B

ML Signal

N/A

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$148.21

Market Cap

21.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLTR
ALNY
Founded
1986
2002
Country
United States
United States
Employees
N/A
115
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1B
21.6B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
DLTR
ALNY
Price
$140.24
$148.21
Analyst Decision
Hold
Buy
Analyst Count
30
30
Target Price
$137.67
★ $284.96
AVG Volume (30 Days)
1.9M
★ 3.0M
Earning Date
11-24-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
144.33
★ 206.88
EPS
4.44
★ 18.42
Revenue
★ $19,411,800,000.00
$1,037,418,000.00
Revenue This Year
$6.56
$46.29
Revenue Next Year
$6.07
$17.46
P/E Ratio
$31.62
★ $8.31
Revenue Growth
10.43
★ 22.88
52 Week Low
$85.88
$149.18
52 Week High
$148.54
$479.79

Technical Indicators

Market Signals
Indicator
DLTR
ALNY
Relative Strength Index (RSI) 56.96 27.53
Support Level $114.36 N/A
Resistance Level $148.54 $235.28
Average True Range (ATR) 5.79 7.83
MACD -0.20 0.45
Stochastic Oscillator 46.16 9.72

Price Performance

Historical Comparison
DLTR
ALNY

About DLTR Dollar Tree Inc.

Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: